Navigation Links
Schering-Plough Reports Financial Results for 2009 Second Quarter
Date:7/21/2009

KENILWORTH, N.J., July 21 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported financial results for the 2009 second quarter.

"Our successful diversification strategy and strong execution by our people have given us the strength to again power through tough challenges - delivering operational sales growth and reconciled earnings-per-share growth for the second quarter," said Fred Hassan, chairman and CEO.

"Meantime, we can see that six years of focus and investment in our R&D pipeline have created enormous long-term value," said Hassan. "Our rich late-stage pipeline continues to advance. We continue to achieve positive regulatory actions in major markets - for example, the recent approval of two products - ASMANEX and REMERON - on the same day in Japan, and a recommendation for approval in Europe of SIMPONI, a novel biologic treatment for inflammatory diseases. In our industry, long-term strength comes from creating a continuous flow of new innovations. We are proud that we have created such a strong and productive R&D engine at Schering-Plough."

For the 2009 second quarter, Schering-Plough reported net income available to common shareholders of $633 million or 38 cents per common share on a GAAP basis. Earnings per common share for the 2009 second quarter would have been 46 cents on net income of $769 million on a reconciled basis, which excludes purchase accounting adjustments related to the acquisition of Organon BioSciences (OBS) and special, merger- and acquisition-related items. For the 2008 second quarter, Schering-Plough reported net income available to common shareholders of $424 million or 26 cents per common share on a GAAP basis and earnings of 45 cents per common share on a reconciled basis.

<
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , September 18, 2014 ... ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced the ... - Global Strategic Business Report" ... http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes the worldwide ... Million by the following Product Segments: ...
(Date:9/18/2014)... September 18, 2014 On Tuesday, Secretary ... Sen. Jim Risch for National Lab Day on the ... across the national laboratory system. Durbin and Risch also ... to increase awareness of the reach of the national ... discoveries to address some of our nation's most pressing ...
(Date:9/18/2014)... 2014 Research and Markets ... N-acetylcysteine Industry Report 2014" report to their ... Report 2014 is a professional and in-depth study ... industry. The report provides a basic ... and industry chain structure. The N-acetylcysteine market analysis ...
(Date:9/18/2014)... DUBLIN , Sept. 18, 2014 ... the "Global Companion Diagnostics (Polymerase Chain Reaction, In-situ ... report to their offering. The ... a CAGR of 22.7% from 2014 to 2019. Factors ... treatment, growing adoption of companion diagnostics by the pharmaceutical ...
Breaking Biology Technology:Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 3Global N-acetylcysteine Industry Report 2014 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3
... March 21, 2011 United Therapeutics Corporation (Nasdaq: ... in its FREEDOM-C(2) registration trial was completed on ... 16-week, multi-center, international, double-blind, randomized, placebo-controlled study of ... (UT-15C) in pulmonary arterial hypertension (PAH) patients receiving ...
... nation that controls magnetism will control the universe," famed ... an overstatement, but there,s little doubt the nation that ... is going to have a serious leg-up on its ... to store and transfer information is the spintronic grand ...
... Inc. (Nasdaq: BMRN ) announced today preliminary ... in an abstract (Abstract #91 , Mental Health Screening ... MD at the 2011 annual American College of Medical ... funded by a grant from BioMarin, is the first ...
Cached Biology Technology:United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial 2Enhancing the magnetism 2Enhancing the magnetism 3First-of-Its-Kind Study Suggests Importance of Routine Mental Health Screening in the Care of Patients Suffering From Genetic Disease PKU 2First-of-Its-Kind Study Suggests Importance of Routine Mental Health Screening in the Care of Patients Suffering From Genetic Disease PKU 3First-of-Its-Kind Study Suggests Importance of Routine Mental Health Screening in the Care of Patients Suffering From Genetic Disease PKU 4First-of-Its-Kind Study Suggests Importance of Routine Mental Health Screening in the Care of Patients Suffering From Genetic Disease PKU 5First-of-Its-Kind Study Suggests Importance of Routine Mental Health Screening in the Care of Patients Suffering From Genetic Disease PKU 6First-of-Its-Kind Study Suggests Importance of Routine Mental Health Screening in the Care of Patients Suffering From Genetic Disease PKU 7First-of-Its-Kind Study Suggests Importance of Routine Mental Health Screening in the Care of Patients Suffering From Genetic Disease PKU 8
(Date:9/18/2014)... and creatively manipulate spoken language is unique to humans. ... million years of human evolution to make this possible ... gene we now have," says Wolfgang Enard, Professor of ... to understand the molecular biological basis of language Enard ... of his latest study, undertaken in collaboration with scientists ...
(Date:9/18/2014)... its newborn screening program into a model other states can ... first-ever Newborn Screening Quality Award from the March of Dimes. ... Arizona,s Department of Health Services director, with the award at ... of full transparency for the length of time it takes ... for analysis, and set a target of having 95 percent ...
(Date:9/18/2014)... Eight researchers from several disciplines will be celebrated tonight ... their roles in improving the health of premature infants ... supercomputing revolutions. The researchers, whose work was supported by ... and the former Atomic Energy Commission, will be honored ... Washington, DC. A bipartisan group of Members of Congress ...
Breaking Biology News(10 mins):Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 33rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2
... NIH-supported scientists will be presenting their latest research findings ... Research in Otolaryngology (ARO). When: February 19-23, 2011 ... Additional Information: Research topics to be presented by scientists ... Communication Disorders (NIDCD) will include: Deafness ...
... will disappear by 2200 as a result of warming ... says a new study by the University of Colorado ... The carbon resides in permanently frozen ground ... warming temperatures, which will impact not only the climate ...
... Scientists are reporting for the first time that ... potential to act as endocrine disruptors, which can interfere ... is not caused by microcystin toxins, long recognized as ... yet unidentified substances. As a result, the scientists are ...
Cached Biology News:NIDCD research at ARO Midwinter Meeting 2NIDCD research at ARO Midwinter Meeting 3NIDCD research at ARO Midwinter Meeting 4NIDCD research at ARO Midwinter Meeting 5NIDCD research at ARO Midwinter Meeting 6NIDCD research at ARO Midwinter Meeting 7Thawing permafrost likely will accelerate global warming 2Thawing permafrost likely will accelerate global warming 3
... Slotted migration Chamber lid allows easy gel observation ... connectors for easy set up between power supply ... current flow if the lid is removed at ... durability., Remote control can be easily ...
... ProFound Label Transfer Sulfo SBED Protein:Protein Interaction ... as Label Transfer has rapidly gained traction ... interaction discovery. A growing number of publications ... Label Transfer Reagent to study a variety ...
... compact benchtop and stackable multi-function incubator. ... a large display screen to accurately ... circulation inside to evenly distribute temperature ... easily calibrated from the microprocessor controller. ...
... label transfer is fast emerging as a ... and confirmation. Until now, only amino groups ... label transfer reagents such as our Sulfo-SBED. ... Mts-Atf-LC-Biotin, are exciting additions to the protein ...
Biology Products: